This website uses cookies in order to maximize its functionality and to provide you with better user experience.

Closing this window or continuing to navigate in the website means that you understand and accept the use of cookies in the website. 

Close
Roche Navigation Menu Roche4Med : Roche4Med
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Products
      Products Overview
    • Congresses & Events
      Congresses & Events Overview
    • Comprehensive Genomic Profiling
      Comprehensive Genomic Profiling Overview
    Close

    1 - of results for ""

    No results

    Are you registered? Register now to view Roche scientific information for HCPs!

    • Clinical Data

      Read more

    • Tecentriq®
    • Mechanism of Action
    • Clinical Data
      • Non-small cell lung cancer
    • Dosing & Administration
    • AR Management
    • Resources
      • Professional Resources
      • Congresses
    • Safety Information
    • References
    • More
      • Mechanism of Action
      • Clinical Data
      • Dosing & Administration
      • AR Management
      • Resources
      • Safety Information
      • References

    You are here:

    1. Products
    2. Tecentriq®
    3. Clinical Data
    4. Non-small cell lung cancer
    5. OAK Study Efficacy

    Oak Study Efficacy

    THE LONGEST MEDIAN OS OF ~14 MONTHS OBSERVED IN ITT

    More than half of patients were alive at 1 year with TECENTRIQ1

    Superior survival regardless of PD-L1 expression1,2 

    Median OS Regardless of PDL-1 Expression

    IC=tumour-infiltrating immune cell; ITT=intent to treat; TC=tumour cell.

    Tecentriq©: Superior 2-years overall survival with durable benefit

    TECENTRIQ®: DURABLE RESPONSE IN PREVIOUSLY TREATED ADVANCED NSCLC


    Median DOR more than doubled with TECENTRIQ1

    DOR=duration of response; NE=not estimable.

     

    • Median follow-up time was 19 months

    Related Links

    OAK Study Design

    Safety Profile

    Dosing and Administration

     

    atezolizumab 2nd line therapy in metastatic NSCLC patients - New analysis from OAK trial 

    References:

    1. TECENTRIQ prescribing information.

    2. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.  

     

    MatCode Approval No.: -1905-V2-3253

    Share
    Close

    Important notice!

    This website is intended for the use of healthcare professionals only, Please approve that you are a healthcare professional in order to continue using this website.

    Accept Cancel
    • © 2021 Roche Pharmaceuticals (Israel) Ltd.
    • 03.08.2020
    • Legal Information

    • Find us on YouTube